[Effects of GLP-1 receptor agonists on carbohydrate metabolism control]

Med Clin (Barc). 2014 Sep:143 Suppl 2:18-22. doi: 10.1016/S0025-7753(14)70104-6. Epub 2014 Oct 15.
[Article in Spanish]

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists are a new group of drugs for the treatment of type 2 diabetes mellitus (DM2). In the present article, we review the available evidence on the efficacy of GLP-1 receptor agonists as glucose-lowering agents, their place in therapeutic algorithms, and the clinical factors associated with a favorable treatment response. Finally, we describe the clinical characteristics of patients who may benefit from these drugs.

Keywords: Agonista del receptor del péptido similar al glucagón; Diabetes; Diabetes mellitus; Efficacy; Eficacia; Exenatida; Exenatida semanal; Exenatide; Glucagon-like peptide-1 receptor agonist; Hipertensión; Hipoglucemias; Hypertension; Hypoglycemias; Liraglutida; Liraglutide; Lixisenatida; Lixisenatide; Obesidad; Obesity; Weekly exenatide.

Publication types

  • Review

MeSH terms

  • Blood Glucose / analysis
  • Carbohydrate Metabolism / drug effects*
  • Clinical Trials as Topic
  • Consensus Development Conferences as Topic
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism
  • Drug Substitution
  • Drug Synergism
  • Drug Therapy, Combination
  • Glucagon-Like Peptide 1 / physiology*
  • Glucagon-Like Peptide-1 Receptor
  • Glycated Hemoglobin / analysis
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / administration & dosage
  • Insulin / therapeutic use
  • Metformin / therapeutic use
  • Multicenter Studies as Topic
  • Patient Selection
  • Receptors, Glucagon / agonists*
  • Spain

Substances

  • Blood Glucose
  • GLP1R protein, human
  • Glucagon-Like Peptide-1 Receptor
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Insulin
  • Receptors, Glucagon
  • Glucagon-Like Peptide 1
  • Metformin